LncRNA HOXA-AS2 and its molecular mechanisms in human cancer

Publication date: Available online 4 July 2018Source: Clinica Chimica ActaAuthor(s): Jicai Wang, Zhilei Su, Shounan Lu, Wen Fu, Zhifa Liu, Xingming Jiang, Sheng TaiAbstractLong non-coding RNAs (lncRNAs), are a novel class of noncoding RNAs, and are commonly defined as RNA molecules greater more than 200 nucleotides in length. Emerging research has indicated that lncRNA played a vital role in the pathophysiology of human tumorigenesis and progression by serving as tumor oncogenes or suppressors either oncogenes or tumor suppressor genes. LncRNA has been shown to get involved in participate various biological processes, such as cell growth, anti-apoptosis, migration and invasion. LncRNA HOXA cluster antisense RNA2 (HOXA-AS2) is a novel cancer-related lncRNA. that It was recently found to exhibit aberrant expression in a variety of malignancies, including breast cancer, gastric cancer, gallbladder carcinoma, hepatocellular carcinoma and pancreatic cancer. The oncogenicity of lncRNA HOXA-AS2 is mainly inhibition or promotion the expression of related genes through direct or indirect way The oncogenicity of lncRNA HOXA-AS2 mainly inhibits or promotes the expression of related genes through direct or indirect pathways, suggesting that HOXA-AS2 is likely represents a feasible biomarker or therapeutic target in human cancers. In this review, we summarize current evidence evidences regarding concerning the biological functions and mechanisms of HOXA-AS2 during tumor development.

Source: Clinica Chimica Acta - July 5, 2018 Category: Laboratory Medicine Source Type: research